Velaresol
Based on 1 Customer Validation
Velaresol (BW 12C) is a small molecule oxyhemoglobin stabilizer. Velaresol stabilizes hemoglobin’s oxy-conformation, shifts oxygen dissociation curves left, induces tumor hypoxia, alters radiosensitivity, protects normal tissues from radiation damage, and reduces sickled cell counts. Velaresol can be used for the research of cancer and sickle cell disease.
For research use only. We do not sell to patients.
- Purity: 99.59%
- CAS No.: 77858-21-0
- Formula: C12H14O5
- Molecular Weight:238.24
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Covalent Screening Library
HY-L036
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Human Metabolite Library
HY-L123
-
Cysteine Targeted Covalent Library
HY-L153
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Covalent Fragment Library
HY-L909
-
Lysine Focused Covalent Fragment Library
HY-L915
-
Multifunctional Covalent Fragment Library
HY-L916
Biological Activity
Velaresol (5 mM; 30 min pre-incubation under air) increases the O2 affinity of Hb in human HbA red blood cells, reducing the P02 required for half-maximal O2 saturation to 7 mmHg[4].
Velaresol (5 mM; 30 min pre-incubation under air) preserves KCC1 activity at low oxygen tensions in human HbA red blood cells, uncoupling transporter function from both oxygen tension and haemoglobin O2 saturation[4].
Velaresol (1.5-5.0 mM; 30 min) increases erythrocyte deformability and reduces sickled cell formation in washed erythrocytes from homozygous SS, S/C, S/β0-thalassaemia, and S/hereditary[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Velaresol (70 mg/kg; i.p.; single dose) induces transient reductions in tumor blood flow and hemoglobin oxygen affinity in mice with rhabdomyosarcoma[2].
Velaresol (70 mg/kg; i.p.; single dose) alters hemoglobin oxygen affinity in WHT mice but has no significant effect on Fib/T tumor blood flow or radiosensitivity[2].
Velaresol (70 mg/kg; infusion) reduces relative tumour tissue perfusion, muscle tissue perfusion, while increasing skin blood flow in mice bearing RIF-1 tumors[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C3H mice (female) inoculated with RIF-1 cells[1]
-
Dosage:70 mg/kg
-
Administration:i.v.; single dose
-
Result:Did not alter RIF-1 tumor thermosensitivity at any tested temperature.
Had no effect on cell survival or cell yield on its own.
Reduced relative blood flow in leg tumors and flank tumors.
Left relative blood flow unchanged in leg muscle, liver, and spleen.
-
Animal Model:BALB/c mice (female, 6-8 weeks old, 19.5 g) with rhabdomyosarcoma[2]
-
Dosage:70 mg/kg
-
Administration:i.p.; single dose
-
Result:Caused a reversible left shift of the oxygen-hemoglobin dissociation curve.
Reduced P50 significantly lower than controls at 1 hour and returned to control levels by 3 hours.
Decreased tumor blood flow significantly at 20 minutes, 1 hour, and 3 hours post-administration.
Decreased tumor growth delay after 25 Gy radiation significantly when radiation was delivered at 20 minutes and 1 hour post-administration.
Showed no significant difference in tumor growth delay from controls at 3 hours post-administration.
Increased tumor growth delay significantly greater than controls when radiation was delivered at 5 hours post-administration.
-
Animal Model:WHT mice (female, 6-8 weeks old, 19.5 g) with Fib/T tumor[2]
-
Dosage:70 mg/kg
-
Administration:i.p.; single dose
-
Result:Caused a reversible left shift of the oxygen-hemoglobin dissociation curve, with maximum P50 decrease at 20 minutes post-injection.
Reduced P50 significantly lower than controls at 1 hour and returned to control levels by 3 hours.
Did not significantly alter Fib/T tumor blood flow at any tested time point.
Did not significantly change the radiation-induced growth delay of clamped or unclamped Fib/T tumors.
Did not alter radiation-induced tumor cell survival fractions for clamped or unclamped tumors.
-
Animal Model:Mice bearing RIF-1 tumors[6]
-
Dosage:70 mg/kg
-
Administration:infusion; assessed 1 hour after administration
-
Result:Reduced relative tumour tissue perfusion by 84%.
Reduced relative muscle tissue perfusion by 86%.
Increased skin blood flow by up to 117%.
Chemical Information
-
CAS No. 77858-21-0
-
Appearance Solid
-
Molecular Weight 238.24
-
Formula C12H14O5
-
Color Light yellow to light brown
-
SMILES
OC(CCCCOC1=C(C(O)=CC=C1)C=O)=O
-
Synonyms
BW 12C; 12C79; BW 12C79
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 125 mg/mL (524.68 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Honess DJ, et al. Effect of the manipulation of oxyhemoglobin status by BW12C on tumor thermosensitivity and on blood flow in tumor and normal tissues in mice. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1187-90. [Content Brief]
[3]. van den Aardweg GJ, et al. Modification of the radiation response of pig skin by manipulation of tissue oxygen tension using anesthetics and administration of BW12C. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1191-4. [Content Brief]
[5]. Kenny MW, et al. Preservation of deformability (filterability) of sickle cells by BW12C during progressive deoxygenation. Br J Haematol. 1983 Nov;55(3):465-71. [Content Brief]
[6]. Falk SJ, et al. BW12C perturbs normal and tumour tissue oxygenation and blood flow in man. Radiother Oncol. 1994 Sep;32(3):210-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1974 mL | 20.9872 mL | 41.9745 mL | 104.9362 mL |
| 5 mM | 0.8395 mL | 4.1974 mL | 8.3949 mL | 20.9872 mL | |
| 10 mM | 0.4197 mL | 2.0987 mL | 4.1974 mL | 10.4936 mL | |
| 15 mM | 0.2798 mL | 1.3991 mL | 2.7983 mL | 6.9957 mL | |
| 20 mM | 0.2099 mL | 1.0494 mL | 2.0987 mL | 5.2468 mL | |
| 25 mM | 0.1679 mL | 0.8395 mL | 1.6790 mL | 4.1974 mL | |
| 30 mM | 0.1399 mL | 0.6996 mL | 1.3991 mL | 3.4979 mL | |
| 40 mM | 0.1049 mL | 0.5247 mL | 1.0494 mL | 2.6234 mL | |
| 50 mM | 0.0839 mL | 0.4197 mL | 0.8395 mL | 2.0987 mL | |
| 60 mM | 0.0700 mL | 0.3498 mL | 0.6996 mL | 1.7489 mL | |
| 80 mM | 0.0525 mL | 0.2623 mL | 0.5247 mL | 1.3117 mL | |
| 100 mM | 0.0420 mL | 0.2099 mL | 0.4197 mL | 1.0494 mL |
Velaresol Related Classifications
HY-106509 Related Classifications
Powered by Bioz